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Abstract
Purpose The purpose of this investigation was to synthe-
size a series of carbonate and carbamate derivatives of
4-demethylpenclomedine (DM-PEN), the major plasma
non-toxic metabolite of penclomedine (PEN) seen in
patients. DM-PEN has been observed to be an active anti-
tumor agent in mouse human xenograft tumor models and
non-neurotoxic in a rat model, however, activity in intracra-
nially implanted human glioma xenograft models have not
been reported. The major goal was to identify derivatives
that are active in brain tumors.
Methods Derivatives were prepared from DM-PEN and
evaluated in vivo against human U251 glioblastoma, D54
glioblastoma and MX-1 breast tumor xenografts and mam-
mary tumor 16/C that were implanted in the mammary fat
pad or intracranially (IC).
Results Carbonate and carbamate derivatives were found
to be superior to DM-PEN against IC growing human
glioblastoma xenografts.
Conclusion The activity of the carbonates and carbamates
against human tumor xenografts in vivo suggests consideration
of these two series of derivatives of DM-PEN for clinical
development.
Keywords Penclomedine · 
4-Demethylcholesteryloxycarbonylpenclomedine · 
Antitumor evaluation in vivo · Human tumor xenografts
Introduction
Penclomedine (PEN) has been evaluated in phase I clinical
trials at Johns Hopkins University Oncology Center, the
University of Wisconsin Comprehensive Cancer Center
and Western General Hospital in Edinburgh [1–5] for pos-
sible use in the treatment of breast cancer and gliomas. This
was based on activity against human breast tumor xeno-
grafts and experimental mammary tumor models, and
against tumor xenografts growing intracranially (IC) in
mice [6, 7]. In all of these clinical trials, dose-limiting
neurotoxicity was observed after both intravenous and oral
administration and was related to peak plasma levels of
PEN [1–4]. 4-Demethyl-penclomedine (DM-PEN) was
identiWed as the major plasma metabolite in patients and
rodents [4, 8–10], and neuroanatomic studies with PEN and
DM-PEN in rats revealed cerebellar damage only in the
PEN-treated group [11, 12].
These observations led to the evaluation of DM-PEN as
therapy versus intracranially implanted and growing glioma
xenograft models [10, 13]. DM-PEN did demonstrate an
improved percentage ILS, but no complete responses were
noted when administered intraperitoneally (IP) to mice
bearing intracranially (IC) implanted human U251 gliomas
and MX-1 breast cancer xenografts [14]. A series of acyl
derivatives of DM-PEN have been synthesized and evalu-
ated against several human tumor xenografts including the
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activity [15]. Subsequently, a series of thiolo-, thiono- and
dithiocarbonate and thiocarbamate analogs of 4-DM-PEN
have been synthesized and evaluated in human MX-1
breast tumor xenografts implanted in the mammary fat pad.
Antitumor activities were comparable to the acyl-DM-PEN
derivatives [16]. The results of the latter study have
prompted the description of the synthesis and antitumor
proWles for a series of carbonate and carbamate analogs,
which have been compared with IC implanted MX-1 breast
tumor, U251 and D54 human glioblastoma multiforme
xenografts, revealing potent activity [16]. The presence of a
high-energy carbonate linker in some of the analogs may be
an inXuencing factor in the activities seen for this group in
view of the energy requirements for gliomas and CNS-
associated neoplasia [17]. The present anticancer data are
presented in support of the clinical development of a
cholesterol carbonate derivative of DM-PEN–DM-CHOC–
PEN.
Materials and methods
4-Demethyl-penclomedine was prepared by a modiWcation
of the reported method as a white, crystalline solid, which
was characterized by mass spectral, NMR and elemental
analysis [10].
A general experimental procedure for the preparation of
the carbonate and carbamate derivatives of DM-PEN was
as follows: DM-PEN (1 g) in 15 ml dry dichloromethane
was treated with 0.5 ml triethylamine followed by one
equivalent of a chlorocarbonate or a carbamoyl chloride,
respectively (obtained from Sigma-Aldrich), in 5 ml dry
dichloromethane, added dropwise with stirring at ¡78°C.
The reaction mixture was stirred for 3 h at ¡78°C and the
solvent removed by evaporation in vacuo. The residue was
triturated with 5 ml acetone and Wltered to remove triethyl-
amine hydrochloride. The acetone Wltrate was concentrated
to 1 ml and separated by preparative thin layer chromatog-
raphy (TLC) on silica gel in a hexane:methylene chloride
solvent (1:1 v/v). The major UV-visible band was collected
and eluted with THF, and the solvent evaporated to dryness
in vacuo. The residue was characterized by mass spectral
(FABMS), NMR (H) and elemental (CHN) analysis. If the
product was not analytically pure, it was separated again by
preparative TLC for subsequent re-analysis. Most products
did not require a second TLC puriWcation step, and a high
yield was obtained. Characterization was provided by mass
spectrometry, which reveals the appropriate mass number
+1 corresponding to the expected structure, and TLC,
which yields a single UV-visible component.
Chemical characterizations of the derivatives are avail-
able upon request (LRM1579@aol.com). DM-CHOC-PEN
has been selected for clinical trials; m.p., NMR (varian
unity) and CHN elemental analyses are presented below
and MS (Perkin Elmer Series 200) in Fig. 1: m.p. 171–
172°C); anal. C35H48Cl5NO4: calc. C, 58.9, H, 6.7, N, 1.9;
found: 58.7, H, 6.9, N, 1.8; 13C-NMR (400 MHz, varian
unity, CDCl3)  155.568, 153.879, 149.261, 147.659, 138.614,
123.545, 117.544, 114.879, 95.622, 80.831, 56.673, 56.156,
55.472, 49.980, 42.341, 39.726, 39.544, 37.665, 36.769,
36.551, 36.216, 35.815, 31.933, 31.860, 28.255, 28.044,
27.469, 24.315, 23.878, 22.859, 22.611, 21.104, 19.312,
18.773, and 11.920 ppm; 1H-NMR(400 MHz, varian unity:
 5.428 (1H, d, J = 6.4 Hz), 4.629 (1H, m), 4.113 (3H, s),
2.516 (2H, m), and between 0.6 and 2.1 ppm multiple signals
for all other hydrogen.
Antitumor evaluation in vivo
Antitumor evaluations were conducted as described previ-
ously [10, 15]. Athymic NCr-nu/nu and B6C3F1 mice were
obtained from various suppliers under contract with NCI
and were housed in sterile, Wlter-capped microisolator
cages in a barrier facility at SRI. Human tumors were
obtained from the NCI Tumor Repository (Frederick, MD,
USA). For IP injection into mice, DM-PEN and the deriva-
tives were prepared in a vehicle of 3% Klucel (hydroxypro-
pyl cellulose) and 1.92% Tween 80 in saline, as a smooth
suspension. MX-1 and 16/C breast tumor fragments (30–
40 mg) from in vivo passage were implanted SC into the
mammary fat pad of the mice. For IC implants, mice were
sedated with ketamine, placed in a Kopf stereotaxic frame,
over the dorsum of the skull, skin and calvarium bone were
reXected under sterile conditions and 0.03 ml of MX-1
breast cancer, or U251 or D54 human glioma brei (contain-
ing 106 cells) injected into the right hemisphere of the mice
via a 0.25 inch 25-gauge stainless steel needle with angling
toward the center of the brain. Bone chips and skin clips
were placed in the brain cavity/skin to control bleeding and
allow healing. Morbidity was rare and tumor take-rate was
typically ca. 100%.
Treatment of groups of Wve mice each was initiated
when the SC tumors reached approximately 300 mg in
subcutaneous (SC) mass size (or on the 5th day after
IC implantation) and was continued for 5 days or
Q4 days £ 3. Each SC growing breast tumor was measured
by caliper in two dimensions twice weekly and converted to
Fig. 1 Where: PEN, R = CH3 
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of tumor growth delay in comparison to a vehicle-treated
control, tumor regressions (partial and complete), and
tumor-free survivors (documented at autopsy). Experiments
were terminated when the control tumors attained a size of
1 g (or if animals demonstrated morbidity) which is typi-
cally 57–61 days. Mice were monitored daily for survival
and morbidity symptoms. Antitumor activity was assessed
on the basis of the percentage increase in lifespan (% ILS),
long-term survivors and presence of tumor, in comparison
to vehicle-treated controls. All animals were examined for
degree of tumor involvement at the time of death. The %
ILS refers to the median day of death or sacriWce due to
morbidity for treated versus controls; excluding long-term
survivors (% LTS)—animals with complete responses and
normal activity at termination of the study. The presence of
a plus (+) before the % ILS indicates animals still alive and
without morbidity at the time of study termination. BCNU
was used as a positive control (IP administration). Temozo-
lamide (TMZ, Temodar) was included (PO administration)
as a control in the U251 glioma studies. DM-acetyl-PEN,
which is not a carbonate or carbamate was also included in
the U251 studies (15).
Multiple doses of each derivative were evaluated in each
tumor model referenced in Tables 1, 2, 3, 4 and 5. Doses
selected in Tables 1, 2, 3, 4 and 5 were for the best
response in that model. Animals bearing diVerent tumors
seemed to tolerate varying concentrations of derivatives,
e.g. DM-CHOC-PEN and DM-BOC-PEN.
Results
Figures 2 and 3 show the structures, MS and yields of the
carbonate and carbamate derivatives of DM-PEN prepared
as described in “Materials and methods”. The vehicle for
all the derivatives was as described in the “Materials and
methods”, and tolerated well, however, in the human
studies a soybean oil/egg yolk lecithin based-vehicle will
be used to deliver the derivatives as an emulsion.
The derivatives were evaluated against Wve separate
mouse tumor models—(Tables 1, 2, 3, 4, 5). A range of IP
Table 1 Activity of derivatives of DM-PEN versus intracerebrally (IC) implanted U251 glioblastoma xenograft tumors in mice
a An acyl derivative—4-demethyl-tetramethylglucuronyl-PEN
Implant: 106 cells IC; treatment route: intraperitoneal (-5 days post IC implant); schedule: q1d £ 5d; species: athymic NCr/nu mice—adult, female,
Charles River 5-mice/group
Drug Dose (mg/kg) Schedule/route Percentage increase 
life span (% ILS)
Percentage long term 
survivors (% LTS)
Control Vehicle Q1D £ 5; IP 0 0/5
DM-PEN 90 (> is toxic) q +17 0/5
DM-BOC-PEN 90 q +15 0/5
DM-NBOC-PEN 90 q +27 0/5
DM-CHOC-PEN 135 q +54 20 (1/5 CR)
DM-COC-PEN 90 q +4 0/5
DM-acetyl-PEN 90 q +38 0/5
(DM-PEN)2–CO 135 q +15 0/5
DM-GLUC-PENa 135 q +4 0/5
DM-DMC-PEN 135 q +21 0/5
BCNU 9 (> is toxic) q 33 - +92 20 (1/5 CR)
TMZ 120 QD £ 5; PO +59 20 (1/5 CR)
Table 2 Activity of carbonate derivatives of DM-PEN versus intracerebrally (IC) implanted D54 glioblastoma xenograft tumors in mice
Implant: 106 cells IC; treatment route: intraperitoneal (-5 days post IC implant); schedule: q1d £ 5d; species: athymic NCr/nu mice—adult, female,
Charles River 5-mice/group
Drug Dose (mg/kg) Schedule/route Percentage increase 
life span (% ILS)
Percentage long term 
survivors (% LTS)
Control Vehicle QD £ 5; IP 0 0/10
DM-BOC-PEN 135 q +23 0/5
DM-CHOC-PEN 200 q +53 1/6
DM-NBOC-PEN 200 q +13 0/5
BCNU 9 (> is toxic) q 33 0/5123
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including the maximum tolerated dose, when known. Several
of the carbonate derivatives yielded complete responses
and produced tumor-free survivors. The derivatives were
tested (in the model available) as they were synthesized.
Not all derivatives were screened versus the same tumor
model.
The cholesterol carbonate derivative, DM-CHOC-PEN,
was evaluated against intracranially implanted U251
human glioblastoma xenograft and was observed to have
improved activity versus the other derivatives [15].
DM-CHOC-PEN was also evaluated against intracranially
implanted D54 human glioblastoma multiforme, a highly
resistant brain tumor, and yielded a 1/6 complete response,
modest but improved over that observed with BCNU, the
current drug of choice for clinical treatment of malignant
gliomas, the major brain tumor in the USA. TMZ was
included in the U251 glioma studies. Comparison of its
activity with other carbonates versus BCNU and TMZ is
available in Table 1. DM-CHOC-PEN in a side-by-side
experiment versus DM-PEN revealed a 54% increase in life
span (ILS), with 20% complete response versus 17% and
no long-term survivors for DM-PEN, respectively.
DM-CHOC-PEN demonstrated activities not only in the
U251 glioma model but also in D54 glioma, MX-1 and 16/
C breast tumor models, (Tables 2, 3, 4). These anticancer
activities continue to support DM-CHOC-PEN as a signiW-
cant candidate for clinical studies.
The antitumor activities for the carbamates are shown in
Tables 1 and 5. Against SC growing MX-1 human mam-
mary tumor xenograft, a dimethyl carbamate derivative,
DM-DMC-PEN, was observed to be equivalent to DM-
PEN in antitumor activity. In the U251 glioma model
activity for DM-DMC-PEN was modest (not as good as
DM-CHOC-PEN), but still improved versus DM-PEN.
Statistical considerations: DM-CHOC-PEN was the only
derivative that consistently produced complete responses in
the U251 glioma model, satisfying our goal to develop
agents for the treatment of brain tumors.
Discussion
Earlier studies demonstrated that DM-PEN was compara-
bly active to PEN against MX-1 human tumor xenografts
but that it lacked the neurotoxicity of PEN in a rat model
[10]. This observation identiWed it as a reasonable candi-
date for derivatization as a means of producing structures
Table 3 Activity of DM-CHOC-PEN versus intracerebrally (IC) implanted MX-1 breast cancer xenograft in mice
Implant: 106 cells IC; treatment route: intraperitoneal (-5 days post IC implant); schedule: q1d £ 5d; species: athymic NCr/nu mice—adult, female,
Charles River 5-mice/group
Drug Dose (mg/kg) Schedule/route Percentage increase 
life span (% ILS)
Percentage long term 
survivors (% LTS)
Control Vehicle QD £ 5; IP 0 0/12
DM-CHOC-PEN 25 q +6 to +20 16 (1/6 CR)
DM-PEN 90 q 60 0/5 CR
PEN 90 q 88 0/5 CR
BCNU 6 q 33 0/5 CR
Table 4 Activities of carbonates of DM-PEN versus intramammary
fat pad (SC) implanted 16/C mammary tumor in mice
Implant: 106 cells SC in mammary fat pad; treatment: initiated—when
tumor mass »300 mg and terminated at »1 g or 57–61 days); species:
B6C3F1—adult/female, Charles River 5–6 mice/group






Control Vehicle Q4D £ 3; IP 0 0
DM-OOC-PEN 90 (> is toxic) q 0 1.7
DM-BOC-PEN 90 q 0 2.2
DM-NBOC-PEN 200 q 0 1.7
DM-CHOC-PEN 135 q 0 2.8
DM-POC-PEN 90 q 0 ¡0.9
DM-CFBOC-PEN 90 q 0 1.9
DM-EOC-PEN 200 q 0 2.3
Table 5 Activity of derivatives of DM-PEN versus subcutaneously
(SC) implanted MX-1 breast cancer xenografts in mice
Implant: 106 cells SC in mammary fat pad; treatment: initiated—when
tumor mass »300 mg and terminated at »1 g or 57–61 days; schedule:











Control Vehicle Q1D £ 5; IP 0 0/5
DM-PEN 135 q >38 5/5
PEN 90 q >41 5/5
DM-MOC-PEN 90 q >41 1/5
DM-acetyl-PEN 90 q >41 5/5
DM-BOC-PEN 90 q >34 1/5
DM-DMC-PEN 135 q >41 5/5123
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and with diminished toxicity. Synthesis of a series of acyl
derivatives was the Wrst attempt to achieve this goal, and
success was indicated by the improved activity against
MX-1 human breast tumor xenografts implanted subcuta-
neously or intracranially, most notably in the latter model
[15].
As a logical extension of this eVort, the present series of
carbonate and carbamate derivatives of DM-PEN have been
prepared by reaction of DM-PEN with the appropriate chlo-
rocarbonate or carbamoyl chloride. Evaluation of several
derivatives of the series against intracranially implanted
human gliomas—U251 and D54—and orthotopically
implanted MX-1 breast cancer, indicated curative activity
for the carbonates and carbamates. The observed reduced
activity for DM-PEN in IC implanted gliomas is consistent
with it being a polar metabolite of PEN and either rapidly
cleared or unable to penetrate the blood-brain barrier. Thus,
the polar nature of the product could prevent it from cross-
ing the blood-brain barrier and cell membranes [14].
A major concern for any of the 4-demethylpenclomedine
(PEN) derivatives is the possibility of neurotoxicity. PEN
was removed from clinical development as a potential drug
for treating gliomas and breast cancer because of its dose-
limiting neurotoxicity. Consequently, DM-CHOC-PEN
was evaluated simultaneously versus PEN in a behavioral
test of neurotoxicity and was observed to be non-neuro-
toxic, as indicated by the absence of production of tremors
in the DM-CHOC-PEN group in comparison to the PEN
group [12, 14]. No observed weight loss or neurotoxicity
(swaying, staggering, seizure activities) was associated
with the DM-CHOC-PEN treatments. The Morris water
maze test results revealed an absence of impaired learning/
memory versus PEN [14]. These studies will also be
included in a preclinical pharmacology and toxicology
paper in preparation [20].
DM-CHOC-PEN is one of the most active DM-PEN
derivatives in the present series versus IC implanted human
glioblastoma and breast cancer xenografts and demon-
strated complete responses in both U251 and D54 glioma
xenograft models. The molecule possesses several interesting
moieties/properties: a high free energy carbonate OCO–O
moiety, a lipophilic cholesteryl moiety and a highly
electrophilic trichloromethane moiety capable of alkylating
nucleophilic sites [14].
A non-classical carbonium ion alkylating mechanism is
proposed for DM-CHOC-PEN’s anticancer activities in
Fig. 4. The scheme describes a dual free radical/carbonium
ion DNA cross-linking mechanism with tumor DNA in the
major groove via N7-guanine resulting in a G-X-C cross-
linking sequence [14]. A bimolecular coupled product (via
the trichloromethylene group) has been identiWed as the
major microsomal metabolite of PEN [10, 14]. The trichlo-
romethylene group is thought to be needed, since a dichlo-
romethylene analog of PEN is not active [does not react
with 4-(p-nitrobenzyl)pyridine (NBP)] (Struck, personnel
communication). No other modiWcations of the moiety have
been studied.
This is in contrast to the free radical and hepatic
activation schemes proposed for PEN and other deriva-
tives [14, 17]. DM-CHOC-PEN is active in vitro versus
glioma and breast cancer cells and does not require prior
activation for anticancer eVectiveness; thus further
support for Fig. 4 [17, 19, 20]. The presence of a lipophilic
cholesteryl moiety in DM-CHOC-PEN may potentiate
its penetration of the central nervous system. DM-
CHOC-PEN has been extracted from U251 glioma tissue
which was dissected from the brains of mice that had
received IP administered DM-CHOC-PEN post IC tumor
cell implantation. The surrounding normal tissue was
negative for drug [17, 20]. Thus additional support for
speculations on DM-CHOC-PEN’s ability to cross the
Fig. 2 Carbonate analogs 
synthesized (MS values)
DM-FOC-PEN R = α-f luorobenzyl (M+H)+ 461; Yield: 39%
DM-COC-PEN R = α-chlorobenzyl (M+H)+ 478; Yield: 65%
DM-BOC-PEN R = benzyl (M+H)+ 444; Yield: 70%
DM-CHOC-PEN R = cholesteryl (M+H)+ 724; Yield: 83%






DM-NBOC-PEN R = p-nitrobenzyl (M+H)+ 490; Yield: 75%
DM-NPOC-PEN R = p-nitrophenyl (M+H)+ 476; Yield: 85%
DM-OOC-PEN R = n-octyl (M+H)+ 466; ; Yield: 72%
DM-POC-PEN R = phenyl (M+H)+ 430; Yield: 69%
DM-MOC-PEN R = methyl (M+H)+ 368; Yield: 65%
(DM-PEN)2 -CO R = DM-PEN (M+H)+ 620; Yield: 52%
DM-PEN + R-OCOCl Et3N







DM-DMC-PEN R = R' = methyl (M+H)+ 381; Yield: 50%
DM-MNC-PEN R = R' = N-morpholinyl (M+H)+ 423; Yield: 62%
DM-MPC-PEN R = methyl, R' = phenyl (M+H)+ 443; Yield: 57%




834 Cancer Chemother Pharmacol (2009) 64:829–835blood-brain barrier and the IC activity reported in this
paper [17].
The carbamate derivatives described were not as active
versus the intracranially growing tumors as were the car-
bonates. Although the two functional groups such as carba-
mates and carbonates are considered to be chemically
isosteric, the availability of a pair of 2p-electrons in the
former actually increases the ease of protonization, reduc-
ing their ability to cross blood-brain barriers versus the car-
bonates [19].
Thus, DM-CHOC-PEN could be administered in combi-
nation with many of the clinically signiWcant DNA major
groove-alkylating drugs, that include methylating agents
[e.g. dacarbazine and temozolomide (Temodar)] and
chloroethylating agents [e.g. bis(chloroethyl)nitrosourea
(BCNU) and clomesone], all of which form carbonium ion-
mediated DNA adducts via O6-guanine [18].
In summary, the anticancer activities observed for the
carbonate and carbamate derivatives of DM-PEN,
described with U251/D54 gliomas and MX-1 breast tumor
implanted intracranially, identify these two classes of deriv-
atives of DM-PEN as potential candidates for clinical
development. The preclinical pharmacology, behavioral
pharmacology and toxicology for DM-CHOC-PEN have
been completed and will be presented in a paper with com-
plete pharmacology, pharmacokinetic analysis and toxicol-
ogy in mice, rats and dogs [20].
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Fig. 4 Proposed mechanism of action of 4-demethyl-4-cholesterol-penclomedine (DM-CHOC-PEN)123
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